<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2902245008
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Andexxa
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        Andexanet alfa
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        46282.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Baxter Pharmaceutical Solutions, LLC " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Baxter Pharmaceutical Solutions, LLC 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AstraZeneca AB 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        V03AB38
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Andexxa contains the active ingredient andexanet alfa. It reverses the effects of certain anticoagulants called factor Xa inhibitors (apixaban or rivaroxaban). Factor Xa inhibitors are given to prevent clots in your blood vessels. Your doctor may decide to give you Andexxa to rapidly reverse the effects of the anticoagulant in case of a life-threatening or uncontrolled bleeding situation.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>if you are allergic to andexanet alfa or any of the other ingredients of this medicine (listed in section 6).</li><li>if you are allergic to hamster proteins</li><li>if you are receiving heparin</li></ul><p><strong>Warnings and precautions</strong><br />Reversing the effect of a factor Xa inhibitor with Andexxa may increase the risk of blood clots. After treatment with Andexxa, your doctor will decide when to restart anticoagulant therapy.</p><p>An independent pro-coagulant effect of andexanet alfa may pose an additional risk of developing thrombosis.<br />If you suffer side effects when you are being given Andexxa by infusion (drip), your doctor may decide to slow down or pause your treatment. Your doctor may give you an antihistamine medicine to help with any side effects (see section 4).</p><p>If a surgery is planned for you which requires anticoagulation with heparin, Andexxa should be avoided.</p><p><strong>Children and adolescents</strong><br />There is no information on the use of Andexxa in children and adolescents.</p><p><br /><strong>Other medicines and Andexxa</strong></p><p>Tell your doctor if you are taking, have recently taken, or might take, any other medicines.<br />This medicine has been designed to reverse the effects of factor Xa inhibitor medicines only. It is unlikely that Andexxa will influence the effect of other medicines or that other medicines will influence Andexxa.<br />Andexxa-treatment should be avoided if anticoagulation with heparin might become necessary.<br />Andexxa causes unresponsiveness to heparin</p><p><strong>Pregnancy and breast-feeding</strong><br />Tell your doctor if you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby.</p><p>Andexxa is not recommended during pregnancy or if you have the potential to become pregnant and are not using birth control.</p><p>Do not breast-feed your child while you are taking this medicine. It is unknown if andexanet alfa is excreted in human milk.</p><p><strong>Driving and using machines</strong><br />This medicine is unlikely to affect your ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>This medicine is for hospital use only.</p><p>Your doctor or nurse will give you this medicine by injection or infusion into a vein.</p><p>Your doctor or nurse will work out the dose of this medicine that you need. This is based on the specific anticoagulant medicine you take as well as on the dose and the time since your last dose of anticoagulant medicine.</p><p>After you have received Andexxa, your doctor will decide when to restart your anticoagulant treatment.</p><p>Detailed instructions for your doctor or nurse on how to give Andexxa are given at the end of this package leaflet (see &lsquo;Handling instructions&rsquo;).</p><p>If you have any further questions on the use of this medicine, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>The most common side effects associated with Andexxa in clinical trials of healthy people were infusion&ndash;related reactions with usually mild symptoms such as flushing or feeling hot (very common side effects which may affect more than 1 in 10 people). Headache, cough, or shortness of breath (common side effects which may affect up to 1 in 10 people) happened within a few minutes to a few hours of the infusion. In clinical trials of patients with life-threatening bleeding, fever and stroke may affect up to 1 in 10 people; transient ischaemic attack (TIA), heart attack, and blood clots in the legs or lungs may affect up to 1 in 100 people (uncommon side effects).</p><p><strong>List of possible side effects<br />Very common (may affect more than 1 in 10 people)</strong></p><ul><li>flushing or feeling hot</li><li>effects on blood clotting markers: some markers which affect blood clotting were increased for a little while and then returned to normal. There were no blood clots in these healthy people.</li></ul><p><strong>Common (may affect up to 1 in 10 people)</strong></p><ul><li>hives</li><li>dizziness</li><li>rapid or irregular heartbeat</li><li>stomach pain or discomfort</li><li>dry mouth</li><li>disturbance of taste</li><li>nausea (feeling sick)</li><li>chest discomfort</li><li>feeling cold</li><li>excessive sweating</li><li>itching</li><li>back pain</li><li>muscle spasms</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>This medicine will be stored in the hospital, and these instructions are intended for hospital staff only.<br />Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the vial and the carton after EXP.<br />The expiry date refers to the last day of that month.<br />Store in a refrigerator (2&deg;C to 8&deg;C).<br />Do not freeze.<br />Once reconstituted, Andexxa is for immediate use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>The active substance is andexanet alfa.</li><li>The other ingredients are Tris base, Tris hydrochloride, L-arginine hydrochloride, sucrose, mannitol, and polysorbate 80.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Andexxa is supplied in glass vials as a white to off-white powder for solution for infusion, which is reconstituted (dissolved) before use. The reconstituted solution is a clear, colorless, or slightly yellow solution.
Each pack contains four vials.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong><br />AstraZeneca AB<br />SE-151 85 S&ouml;dert&auml;lje<br />Sweden<br /><strong>Manufacturer</strong><br />Baxter Pharmaceutical Solutions, LLC<br />927 S. Curry Pike<br />Bloomington, IN 47403, USA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                August 2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي عقار أنديكسا على المادة الفعاّلة أندكسانيت ألفا. وهو يعكس آثار بعض مضادات التخثر التي تسمى مثبطات عامل التخثر العاشر أ (أبيكسابان أو ريفاروكسابان). تعُطى مثبطات عامل التخثر العاشر أ لمنع تكونّ الجلطات في الأوعية الدموية. قد يقرر طبيبك أن يعطيك عقار أنديكسا لعكس آثار مضاد التخثر بسرعة في حالة حدوث نزيف مهدد للحياة أو غير خاضع للسيطرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>إذا كنت تعاني من حساسية تجاه أندكسانيت ألفا أو أي من المكونات الأخرى لهذا الدواء (المُدرجة في القسم 6)</p><p>إذا كنت تعاني من حساسية تجاه بروتينات الهامستر</p><p dir="RTL">إذا كنت تتلقى دواء هيبارين</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">قد يزيد عكس تأثير مثبطات عامل التخثر العاشر أ مع عقار أنديكسا من خطر الجلطات الدموية. بعد العلاج باستخدام عقار أنديكسا، سيقرر طبيبك متى يجب إعادة بدء العلاج بمضاد التخثر.</p><p dir="RTL">قد يشكّل التأثير المستقل المضاد للتخثر لعقار أندكسانيت ألفا خطرًا إضافيًا للإصابة بالتخثر.</p><p dir="RTL">إذا كنت تعاني من آثار جانبية عند تلقي عقار أنديكسا عن طريق التسريب (التنقيط)، فقد يقرر طبيبك إبطاء العلاج أو إيقافه مؤقتًا. قد يعطيك طبيبك دواءً مضادًا للهستامين للمساعدة في علاج أي آثار جانبية (انظر القسم 4).</p><p dir="RTL">إذا تم التخطيط لإجراء جراحة لك تتطلب منع تخثر الدم باستخدام دواء الهيبارين، ينبغي تجنب استخدام عقار&nbsp;أنديكسا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا توجد معلومات عن استخدام عقار أنديكسا في الأطفال والمراهقين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وعقار أنديكسا</strong></p><p dir="RTL">أخبر طبيبك إذا كنت تتناول، أو قد تناولت مؤخرًا، أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">لقد صُمم هذا الدواء لعكس آثار أدوية تأثير مثبطات عامل التخثر العاشر أ فقط. ومن غير المحتمل أن يؤثر عقار أنديكسا على تأثير الأدوية الأخرى أو أن الأدوية الأخرى ستؤثر على عمل عقار أنديكسا.</p><p dir="RTL">ينبغي تجنب العلاج باستخدام عقار أنديكسا إذا كان قد يصبح من الضروري استخدام دواء الهيبارين في منع تخثر الدم. يسبب عقار أنديكسا عدم الاستجابة للهيبارين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والإرضاع الطبيعي</strong></p><p dir="RTL">أخبري طبيبكِ إذا كنتِ حاملاً أو ترضعين رضاعة طبيعية، أو تعتقدين أنكِ قد تكوني حاملا، أو تخططين للإنجاب.</p><p dir="RTL">لا يُوصى باستخدام عقار أنديكسا أثناء فترة الحمل أو إذا كان لديكِ احتمالية الحمل ولا تستخدمين وسائل تحديد&nbsp;النسل.</p><p dir="RTL">لا تُرضعِي طفلكِ أثناء تناول هذا الدواء. فمن غير المعروف ما إذا كان يُفرز عقار أندكسانيت ألفا في حليب الأم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">من غير المحتمل أن يؤثر هذا الدواء على قدرتك على القيادة واستخدام الآلات.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">هذا الدواء مخصص للاستخدام في المستشفى فقط.</p><p dir="RTL">سيعطيك طبيبك أو الممرضة هذا الدواء عن طريق الحقن أو التسريب في الوريد.</p><p dir="RTL">سيحدد طبيبك أو الممرضة جرعة هذا الدواء التي تحتاجها. ويعتمد ذلك على الدواء المحدد المضاد للتخثر الذي تتناوله وكذلك على الجرعة والوقت منذ آخر جرعة تناولتها من الدواء المضاد للتخثر.</p><p dir="RTL">بعد أن تتلقى عقار أنديكسا، سيقرر طبيبك متى يجب إعادة بدء العلاج المضاد للتخثر.</p><p dir="RTL">تم إعطاء تعليمات مفصلة لطبيبك أو الممرضة حول كيفية إعطاء عقار أنديكسا في نهاية نشرة العبوة هذه (انظر &quot;تعليمات التعامل&quot;).</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى حول استخدام هذا الدواء، فتحدّث إلى طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قد يُسبِّب هذا الدواء، شأنه شأن جميع الأدوية، آثارًا جانبية، على الرغم من أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كانت الآثار الجانبية الأكثر شيوعًا المرتبطة بعقار أنديكسا في التجارب السريرية على أشخاص أصحّاء تتمثل في&nbsp;ردود فعل مرتبطة بالتسريب مع أعراض خفيفة عادةً مثل التورّد أو الإحساس بالحرارة (آثار جانبية شائعة جدًا قد تصيب أكثر من شخص واحد من بين 10 أشخاص). حدث صداع، أو سعال، أو ضيق في التنفس (آثار جانبية شائعة قد تصيب ما يصل إلى شخص واحد من كل 10 أشخاص) في خلال دقائق قليلة إلى ساعات قليلة&nbsp;من التسريب. في التجارب السريرية للمرضى الذين يعانون من نزيف مهدد للحياة، قد تصيب الحُمى والسكتة الدماغية ما يصل إلى شخص واحد من كل 10 أشخاص؛ وقد يُصاب ما يصل إلى شخص واحد من كل 100 شخص بالنوبة الإقفارية العابرة (TIA)، والنوبة القلبية، وتجلطات دموية في الساقين أو الرئتين (آثار جانبية غير شائعة).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قائمة الآثار الجانبية المحتملة</strong></p><p dir="RTL"><strong>شائعة جداً (قد تصيب أكثر من شخص واحد من كل 10&nbsp;أشخاص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورّد أو الإحساس بالحرارة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التأثيرات على مؤشرات تخثر الدم: زادت بعض المؤشرات التي تؤثر على تخثر الدم لفترة قصيرة ثم عادت إلى طبيعتها. ولم تكن هناك تجلطات دموية لدى هؤلاء الأشخاص الأصحّاء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة (قد تصيب لغاية شخص واحد من كل 10 أشخاص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشّرى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضربات قلب سريعة أو غير منتظمة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو انزعاج في المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب في حاسة التذوق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان (الشعور بالمرض)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق الصدر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالبرد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعرّق الزائد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكّة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الظهر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التشنجات العضلية</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>سيتم تخزين هذا الدواء في المستشفى، وهذه التعليمات مخصصة لموظفي المستشفى فقط. احفظ هذا الدواء بعيداً عن مرأى الأطفال ومتناولهم.</p><p>&nbsp;لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدونّ على القنينة والعلبة الكرتون بعد كلمة EXP<br />&nbsp;يشير تاريخ انتهاء الصلاحية إلى آخر يوم في هذا الشهر.<br />خزنّ الدواء في الثلاجة (في درجة حرارة بين 2 إلى 8 درجات مئوية).<br />لا تجمد الدواء<br />بمجرد إعادة تكوين عقار أنديكسا، يكون جاهزاً للاستخدام على الفور.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعّالة هي أندكسانيت ألفا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكوّنات الأخرى هي قاعدة تريس، تريس هيدروكلوريد، هيدروكلوريد ل-آرجينين، سكروز، مانيتول، وبوليسوربات 80.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتوفر عقار أنديكسا في قنينات زجاجية في شكل مسحوق أبيض إلى أبيض مائل للأصفر لمحلول للتسريب، والذي يتم إعادة تكوينه (يذاب) قبل الاستخدام. المحلول المُعاد تكوينه عبارة عن محلول شفاف، أو عديم اللون، أو أصفر قليلاً.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل ترخيص التسويق</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">AstraZeneca AB</p><p dir="RTL">SE-151 85 S&ouml;dert&auml;lje</p><p dir="RTL">السويد</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الجهة المصنّعة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">Baxter Pharmaceutical Solutions, LLC</p><p dir="RTL">927 S. Curry Pike</p><p dir="RTL">Bloomington, IN 47403, USA</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            اغسطس 2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Andexxa 200 mg powder for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains 200 mg of andexanet alfa *.
After reconstitution, each mL of solution contains 10 mg of andexanet alfa.
* Andexanet alfa is produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cells.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for infusion White to off-white lyophilized powder
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong>For adult patients treated with a direct factor Xa (FXa) inhibitor (apixaban or rivaroxaban) when reversal of anticoagulation is needed due to life threatening or uncontrolled bleeding.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Restricted to hospital use only.<br /><u>Posology</u><br />Andexanet alfa is administered as an intravenous bolus at a target rate of approximately 30 mg/min over 15 minutes (low dose) or 30 minutes (high dose), followed by administration of a continuous infusion of 4 mg/min (low dose) or 8 mg/min (high dose) for 120 minutes (see table 1).</p><p><strong>Table 1: Dosing regimens</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:612px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Initial</strong><strong> </strong><strong>intravenous</strong><strong> </strong><strong>bolus</strong></p></td><td style="vertical-align:top"><p><strong>Continuous</strong><strong> </strong><strong>intravenous</strong><strong> </strong><strong>infusion</strong></p></td><td style="vertical-align:top"><p><strong>Total</strong><strong> </strong><strong>number</strong><strong> </strong><strong>of</strong><strong> </strong><strong>200 mg vials needed</strong></p></td></tr><tr><td style="vertical-align:top"><p>Low dose</p></td><td style="vertical-align:top"><p>400 mg at a target rate of 30 mg/min</p></td><td style="vertical-align:top"><p>4 mg/min for 120 minutes</p><p>(480 mg)</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>High dose</p></td><td style="vertical-align:top"><p>800 mg at a target rate of 30 mg/min</p></td><td style="vertical-align:top"><p>8 mg/min for 120 minutes</p><p>(960 mg)</p></td><td style="vertical-align:top"><p>9</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Reversal of apixaban</u></p><p>The recommended dose regimen of Andexxa is based on the dose of apixaban the patient is taking at the time of anticoagulation reversal, as well as on the time since the patient&rsquo;s last dose of apixaban (see table 2).</p><p><strong>Table 2: Summary of dosing for reversal of apixaban</strong></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>FXa inhibitor</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Last</strong><strong> </strong><strong>dose</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Timing</strong><strong> of last dose before Andexxa initiation</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&lt; 8 hours or unknown</strong></p></td><td style="vertical-align:top"><p><strong>&ge; 8 hours</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Apixaban</p></td><td style="vertical-align:top"><p>&le; 5 mg</p></td><td style="vertical-align:top"><p>Low dose</p></td><td rowspan="2" style="vertical-align:top"><p>Low dose</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 5 mg/ Unknown</p></td><td style="vertical-align:top"><p>High dose</p></td></tr></tbody></table><p><u>Reversal of rivaroxaban</u></p><p>The recommended dose regimen of Andexxa is based on the dose of rivaroxaban the patient is taking at the time of anticoagulation reversal, as well as on the time since the patient&rsquo;s last dose of rivaroxaban (see table 3).</p><p><strong>Table 3: Summary of dosing for reversal of rivaroxaban</strong></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:624px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>FXa inhibitor</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Last</strong><strong> </strong><strong>dose</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Timing</strong><strong> of last dose before Andexxa initiation</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&lt; 8 hours or unknown</strong></p></td><td style="vertical-align:top"><p><strong>&ge; 8 hours</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Rivaroxaban</p></td><td style="vertical-align:top"><p>&le; 10 mg</p></td><td style="vertical-align:top"><p>Low dose</p></td><td style="vertical-align:top"><p>Low dose</p></td></tr></tbody></table><p>&nbsp;</p><p><em><u>Restarting antithrombotic therapy</u></em></p><p>Following administration of Andexxa and cessation of a major bleed, re-anticoagulation should be considered to prevent thrombotic events due to the patient&rsquo;s underlying medical condition.</p><p>Antithrombotic therapy can be re-initiated as soon as medically indicated following treatment if the patient is clinically stable and adequate haemostasis has been achieved. Medical judgement should balance the benefits of anticoagulation with the risks of re-bleeding (see section 4.4).</p><p>&nbsp;</p><p><em>Special populations</em></p><p><em>Elderly patients (aged 65 years and over):</em> No dose adjustment is required in elderly patients (see section 5.2).</p><p>&nbsp;</p><p><em>Renal impairment: </em>The effect of renal impairment on andexanet alfa exposure levels has not been evaluated. Based on the existing data on clearance, no dose adjustment is recommended.</p><p>&nbsp;</p><p><em>Hepatic impairment: </em>Based on the existing data on clearance of andexanet alfa, no dose adjustment is recommended. The safety and efficacy have not been studied in patients with hepatic impairment (see section 5.2).</p><p>&nbsp;</p><p><em>Paediatric population: </em>The safety and efficacy of andexanet alfa in children and adolescents have not been established. No data are available.</p><p><u>Method of administration</u></p><p><em><u>Intravenous</u></em><em><u> use</u></em></p><p>After an appropriate number of vials of Andexxa has been reconstituted, the reconstituted solution (10&nbsp;mg/mL) without further dilution is transferred to sterile large volume syringes in case a syringe pump is used for administration or to suitable empty intravenous bags comprised of polyolefin (PO) or polyvinyl chloride (PVC) material (see section 6.6). Prior to administration by IV infusion a 0.2 or 0.22&nbsp;micron in-line polyethersulfone (PES) or equivalent low protein- binding filter should be used.</p><p>&nbsp;</p><p>Andexxa is administered as an IV bolus at a target rate of approximately 30 mg/min over 15 to 30 minutes, followed by administration of a continuous infusion of 4 mg (low dose) or 8 mg (high dose) per minute for 120 minutes (see table 1).</p><p>&nbsp;</p><p>For instructions on reconstitution of the medicinal product before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any other ingredients listed in section 6.1. 

Known allergic reaction to hamster proteins.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Limitations of use</u></p><p>Clinical efficacy is based upon reversal of anti-FXa-activity in healthy volunteers dosed with apixaban or rivaroxaban. Andexanet alfa is not suitable for pre-treatment of urgent surgery. Use for edoxaban- or enoxaparin-reversal is not recommended due to lack of data. Andexanet alfa will not reverse the effects of non-FXa inhibitors (see section 5.1).</p><p>&nbsp;</p><p>Treatment monitoring should be based mainly on clinical parameters indicative of appropriate response (i.e., achievement of haemostasis), lack of efficacy (i.e., re-bleeding), and adverse events (i.e., thromboembolic events). Treatment monitoring of andexanet alfa should not be based on anti-FXa-activity. Commercial anti-FXa-activity assays are unsuitable for measuring anti-FXa activity following administration of andexanet alfa as these assays result in erroneously elevated anti-FXa activity levels, thereby causing a substantial underestimation of the reversal activity of andexanet alfa.</p><p>&nbsp;</p><p>Dosage recommendation is based upon data-modelling in healthy volunteers. Validation has not been successful, yet. Data from bleeding patients are limited. Preliminary data suggest higher risk of thrombosis for patients receiving the higher dose of andexanet, previous lower dose of the anti-FXa inhibitor, and patients on rivaroxaban.</p><p>&nbsp;</p><p>In ANNEXA-4, intracranial haemorrhage (ICH) patients (GCS &gt; 7 and haematoma volume &lt; 60&nbsp;mL) have been included. Treatment of patients with more severe ICH with andexanet alfa has not been studied.</p><p>&nbsp;</p><p><u>Thromboembolic and ischemic risks </u></p><p>Treatment with ANDEXXA has been associated with serious and life-threatening adverse events, including: arterial and venous thromboembolic events, ischemic events, including myocardial infarction and ischemic stroke, cardiac arrest, and sudden deaths. Monitor for thromboembolic events and initiate anticoagulation when medically appropriate. Monitor for symptoms and signs that precede cardiac arrest and provide treatment as needed</p><p>&nbsp;</p><p>Patients being treated with FXa inhibitor therapy have underlying disease states that predispose them to thrombotic events. Patients with prior history of stroke, myocardial infarction, or heart failure may be at higher risk of thrombotic events. Reversing FXa inhibitor therapy exposes patients to the thrombotic risk of their underlying disease. In addition, independent pro-coagulant effect of andexanet alfa, mediated by inhibition of tissue factor pathway inhibitor (TFPI), has been demonstrated, which may pose a risk of developing thrombosis. Duration of this effect in bleeding patients is not known. Laboratory parameters as anti- FXa activity, endogenous thrombotic potential (ETP), or markers of thrombosis might not be reliable for guidance. To reduce this risk, resumption of anticoagulant therapy should be considered as soon as medically appropriate after completion of treatment.</p><p>&nbsp;</p><p>In healthy volunteers, dose-dependent increases in coagulation markers F1+2, TAT, and D-dimer, and dose-dependent decreases in TFPI, after administration of andexanet alfa were observed, but no thromboembolic events were reported. These markers were not measured in patients enrolled in the ANNEXA-4 study, but thromboembolic events have been observed (see section 5.1). Monitoring for signs and symptoms of thrombosis is, therefore, strongly recommended.</p><p>&nbsp;</p><p><u>Use of andexanet alfa in conjunction with other supportive measures</u></p><p>Andexanet alfa can be used in conjunction with standard haemostatic supportive measures, which should be considered as medically appropriate.</p><p>&nbsp;</p><p>The safety of andexanet alfa has not been evaluated in patients who received prothrombin complex concentrates, recombinant factor VIIa, or whole blood within seven days prior to the bleeding event, as they were excluded from clinical trials. Pro-coagulant factor treatments (e.g., 3- or 4-factor prothrombin complex concentrate (PCC)/activated PCC, recombinant factor VIIa, fresh frozen plasma) and whole blood should be avoided unless absolutely required, due to lack of data in combination with these treatments.</p><p>&nbsp;</p><p><u>Interaction with heparin</u></p><p>Use of andexanet prior to heparinization e.g. during surgery should be avoided as andexanet causes unresponsiveness to heparin. Use of andexanet as an antidote for heparin or low-molecular weight heparin has not been evaluated and is not recommended (refer to Section 4.5.).</p><p>&nbsp;</p><p><u>Infusion-related reactions</u></p><p>In case of mild or moderate infusion reactions, careful observation may be sufficient. For moderate symptoms, consideration may be given to a brief interruption or slowing of the infusion with resumption of the infusion after symptoms subside. Diphenhydramine may be administered.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Traceability</u></p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies with andexanet alfa have been performed.</p><p>&nbsp;</p><p>In vitro data suggest interaction of andexanet alfa with the heparin- anti-thrombin III (ATIII) complex and neutralization of the anticoagulant effect of heparin. Off-label use of andexanet alfa pre-surgery with intended heparin-anticoagulation has been reported to cause unresponsiveness to heparin (refer to Section 4.4). Use of andexanet as an antidote for heparin or low-molecular weight heparin has not been evaluated and is not recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no data from the use of andexanet alfa in pregnant women. Animal studies are insufficient with respect to reproductive toxicity (see section 5.3). Andexanet alfa is not recommended during pregnancy or in women of childbearing potential not using contraception.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>It is unknown whether andexanet alfa is excreted in human milk. A risk to newborns/infants cannot be excluded. Breast-feeding should be discontinued during treatment with andexanet alfa.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>There are no data on the effects of andexanet alfa on human fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Andexanet alfa has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The safety has been evaluated in clinical trials including 417 healthy subjects administered an FXa inhibitor, as well as in 477 patients in a Phase IIIb/IV trial (ANNEXA-4), who had acute major bleeding and were under treatment with an FXa inhibitor (mostly apixaban and rivaroxaban) , and in Phase 4 study (ANNEXA-I) including 262 ANDEXXA-treated patients presenting with acute intracranial hemorrhage (ICrH) and under treatment with apixaban, rivaroxaban or edoxaban. In ANNEXA-4, the most commonly reported adverse reactions were pyrexia, deep vein thrombosis, and ischemic stroke. In ANNEXA-I, the most commonly reported adverse reactions were pyrexia and ischemic stroke. The safety profile of ANDEXXA was overall consistent across the studies.</p><p>In the clinical trials in healthy subjects administered an FXa inhibitor and then receiving andexanet alfa, no serious or severe adverse reactions were reported. The most frequently observed adverse reactions were mild or moderate infusion-related reactions (see table 4) comprising symptoms such as flushing, feeling hot, cough, dysgeusia, and dyspnoea occurring within a few minutes to a few hours of the infusion. Among the healthy subjects studied, women experienced more adverse reactions (mainly infusion-related reactions) than men.</p><p>&nbsp;</p><p>In the healthy subject trials, elevations &gt; 2 x ULN in D-dimer and prothrombin fragments F1+2 were frequently observed. These elevations were maintained between several hours to a few days following administration, but no thrombotic events were reported. Clinical relevance in the target population (patients with uncontrolled or life-threatening bleeding who are anticoagulated due to high to very high risk of thrombosis) is unknown.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p><u>&nbsp;</u></p><p>Table 4 provides the list of adverse reactions from clinical studies in bleeding patients. The adverse reactions are classified by system organ class (SOC) and frequency, using the following convention: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge;&nbsp;1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000); or not known (cannot be estimated from available data).</p><p>&nbsp;</p><p><strong>Table 4: List of adverse reactions in bleeding patients receiving Andexxa</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>MedDRA System</p><p>Order Class</p></td><td style="vertical-align:top"><p>Very Common</p><p>(&ge; 1/10)</p></td><td style="vertical-align:top"><p>Common</p><p>(&ge; 1/100 to</p><p>&lt; 1/10)</p></td><td style="vertical-align:top"><p>Uncommon</p><p>(&ge; 1/1 000 to</p><p>&lt; 1/100)</p></td><td style="vertical-align:top"><p>Rare</p><p>(&ge; 1/10 000 to</p><p>&lt; 1/1 000)</p></td><td style="vertical-align:top"><p>Very Rare</p><p>(&lt; 1/10 000)</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cerebral infarction, Cerebrovascular accident,</p><p>Ischemic stroke</p></td><td style="vertical-align:top"><p>Transient ischemic attack</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Acute myocardial infarction, Myocardial infarction</p></td><td style="vertical-align:top"><p>Cardiac arrest</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Deep vein thrombosis</p></td><td style="vertical-align:top"><p>Iliac artery occlusion</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pulmonary embolism</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administrative site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Infusion-related reaction<sup>a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><sup>a</sup> reported signs/symptoms (rigors, chills, hypertension, oxygen desaturation, agitation and confusion) were transient and mild to moderate in severity</p><p>&nbsp;</p><p><u>Description</u><u> </u><u>of selected adverse reactions</u></p><p><em>Thrombotic events</em></p><p><em>ANNEXA-4 study</em></p><p>In the ANNEXA-4 study, 50/477 (10.5%) patients experienced one or more of the following adjudicated thrombotic events: cerebrovascular accident (22/50), deep venous thrombosis (12/50), myocardial infarction (9/50), pulmonary embolism (5/50), and transient ischemic attack (2/50). The median time to thrombotic event was 10 days. Nineteen of 50 patients with thrombotic events experienced the thrombotic event during the first 3 days.</p><p>Of the 477 patients who received ANDEXXA, 326 (68.3%) received any form of re-anticoagulation within 30 days after treatment. Of these 326 subjects, 18 received anticoagulation in response to a thrombotic event, while 308 received the anticoagulation as a prophylactic. Of these 308 subjects, 15 (4.9%) had a thrombotic event after resumption of anticoagulation. In the 169 patients who did not receive anticoagulation as a prophylactic, 35 (20.7%) had a thrombotic event.</p><p><em>ANNEXA-I study</em></p><p>In the ANNEXA-I study, adjudicated thrombotic events through 30 days post-randomization were reported in 27 patients (10.3%) in the ANDEXXA group and 15 patients (5.7%) in the usual care group. The difference in rate of thrombotic events between the treatment groups across the pre-defined patient subgroups was generally consistent with the overall population.</p><p>When considering underlying disease history, patients in the ANDEXXA group with a prior history of stroke or myocardial infarction, or history of heart failure, were found to have a numerically higher rate of thrombotic events, compared with patients without a history of these underlying diseases. Of the 78 patients who had a prior history of stroke or myocardial infarction, 10 patients (12.8%) had a thrombotic event, compared with 17 of 184 patients (9.2%) without this medical history. In the 46 patients who had a history of heart failure, 8 patients (17.4%) had a thrombotic event, compared with 19 of 216 patients (8.8%) without this medical history (see Section 4.4).</p><p>Patients in the ANDEXXA and usual care group experienced one or more of the following adjudicated thrombotic events, respectively: ischemic stroke (6.5% versus 1.5%), myocardial infarction (4.2% versus 1.5%), pulmonary embolism (0.4% versus 2.3%), arterial systemic embolism (1.1% versus 0.8%) and deep vein thrombosis (0.4% versus 0.8%). The median time to thrombotic event was 3 and 14 days in the ANDEXXA and usual care group, respectively. In the ANDEXXA group, 14 patients had a thrombotic event during the first 3 days, compared with 1 patient in the usual care group. None of these patients had received any dose of anticoagulant prior to the thrombotic event. Adjudicated thrombotic events leading to death were reported in 6 patients (2.3%) in the ANDEXXA group and 2 patients (0.8%) in the usual care group.</p><p>Overall, 199 patients (76.0%) in the ANDEXXA group and 192 patients (72.5%) in the usual care group were restarted with any anticoagulant within 30 days post-randomization. Of those, 183 patients (92.0%) in the ANDEXXA group and 187 patients (97.4%) in the usual care group received at least one dose of any anticoagulant as a prophylactic measure. In this population, a similar rate of thrombotic events (4.9% and 4.8%) was observed in the ANDEXXA and usual care group, respectively. In the 79 patients in the ANDEXXA group who did not receive any anticoagulation as a prophylactic measure, 18 patients (22.8%) had a thrombotic event, compared with 6 of 78 patients (7.7%) in the usual care group (see Section 4.4).</p><p>To report any side effect(s):</p><ul><li><strong><em>Saudi Arabia: </em></strong></li></ul><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>- </strong>The National Pharmacovigilance Centre (NPC)</p><ul><li>SFDA Call Center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa&nbsp;&nbsp;</li><li>Website: https://ade.sfda.gov.sa/</li></ul></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no clinical experience with overdose of andexanet alfa. No dose-limiting toxicities have been observed during clinical trials.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: All other therapeutic products, antidotes. ATC code: V03AB38</p><p><u>&nbsp;</u></p><p><u>Mechanism of action</u></p><p>Andexanet alfa is a recombinant form of human FXa protein that has been modified to lack FXa enzymatic activity. The active site serine was substituted with alanine, rendering the molecule unable to cleave and activate prothrombin, and the gamma-carboxyglutamic acid (Gla) domain was removed to eliminate the ability of the protein to assemble into the prothrombinase complex, thus removing any anti-coagulant effects.</p><p>&nbsp;</p><p>Andexanet alfa is a specific reversal agent for FXa inhibitors. The predominant mechanism of action is the binding and sequestration of the FXa inhibitor. In addition, andexanet alfa has been observed to bind to, and inhibit tissue factor pathway inhibitor (TFPI). Inhibition of TFPI activity can increase tissue factor-initiated thrombin generation inducing a pro-coagulant effect.</p><p><u>&nbsp;</u></p><p><u>Pharmacodynamic effects</u></p><p>The effects of andexanet alfa can be measured through pharmacodynamic markers, including free fraction of available FXa inhibitor as well as through restoration of thrombin generation. In addition, andexanet alfa has been shown to inhibit TFPI-activity.</p><p>&nbsp;</p><p>Commercial anti-FXa-activity assays are unsuitable for measuring anti-FXa activity following administration of andexanet alfa. Due to the reversible binding of andexanet alfa to the FXa inhibitor, the high sample dilution currently used in these assays leads to dissociation of the inhibitor from andexanet alfa, resulting in detection of erroneously elevated anti-FXa activity levels, thereby causing a substantial underestimation of the reversal activity of andexanet alfa.</p><p>&nbsp;</p><p>In prospective, randomized, placebo-controlled, dose-ranging studies in healthy subjects, the dose and dose regimen of andexanet alfa required to reverse anti-FXa activity and restore thrombin generation for FXa inhibitors (apixaban or rivaroxaban) were determined with modified assays that are not commercially available.</p><p>&nbsp;</p><p>The maximal reversal of anti-FXa activity was achieved within two minutes of completing the bolus administration. Administration of andexanet alfa as a bolus followed by continuous infusion resulted in a sustained decrease in anti-FXa activity. The anti-FXa activity returned to the placebo levels and above approximately two hours after the end of a bolus or infusion dependent on dosage.</p><p>&nbsp;</p><p>When andexanet alfa was administered as a bolus followed by a continuous infusion, the maximum decrease in unbound FXa inhibitors was rapid (within two minutes of the end of the bolus) and was sustained over the course of the infusion then gradually increased over time, reaching a maximum at approximately two hours following the end of infusion.</p><p>&nbsp;</p><p>Restoration of thrombin generation following administration was dose- and dose-regimen-dependent and did not correlate with anti-FXa-activity beyond approximately four hours (see below, &ldquo;restoration of thrombin generation&rdquo;).</p><p>&nbsp;</p><p>Plasma TFPI activity has been shown to be inhibited completely from 2 minutes to 14.5&nbsp;hours after andexanet alfa bolus-administration, and returned to baseline within 3 days. Tissue-factor (TF)-initiated thrombin generation immediately increased above the baseline (prior to anticoagulation) and remained elevated for &gt; 20 hours in contrast to placebo. Plausibility of a pro-coagulant effect of TFPI-inhibition is supported by consecutive and sustained slopes of D-Dimers, TAT, and F1+2.</p><p><u>&nbsp;</u></p><p><u>PK/PD modelling</u></p><p>Bolus strengths of andexanet alfa being necessary to achieve mean unbound apixaban (400 mg bolus) and unbound rivaroxaban concentrations (800 mg bolus) below the anticipated respective threshold for no anticoagulant effect were twice as high for rivaroxaban (20 mg QD) compared to apixaban (5 mg BID), due to the differential PK characteristics and dose levels of respective FXa inhibitor.</p><p><u>&nbsp;</u></p><p><u>Clinical efficacy and safety</u></p><p>The efficacy and safety of andexanet alfa have been evaluated in the following: 1) randomized, placebo-controlled, Phase II dose-ranging trials with healthy volunteers administered FXa inhibitors to establish doses required for reversal; 2) two Phase III studies, one with apixaban and the other with rivaroxaban, to confirm the efficacy of the high and low dose regimens; and 3) a global, multicentre, prospectively defined, open-label Phase IIIb/IV study (ANNEXA-4) in patients with an acute major bleeding episode requiring urgent reversal of FXa anticoagulation.</p><p><em><u>&nbsp;</u></em></p><p><em><u>Reversal of anticoagulation in healthy subjects aged 50-75 (Studies 14-503 and 14-504)</u></em></p><p>In a prospective, randomized, placebo-controlled study, healthy subjects with a median age of</p><p>56.5 years on apixaban 5 mg twice daily received andexanet alfa (n=24) administered as a 400 mg IV bolus immediately followed by a 4 mg per minute IV infusion for 120 minutes (480 mg) or placebo (n=8).</p><p>&nbsp;</p><p>In a similar study, subjects with a median age of 57 years on rivaroxaban 20 mg daily received andexanet alfa (n=26) administered as an 800 mg IV bolus immediately followed by an 8 mg per minute IV infusion for 120 minutes (960 mg) or placebo (n=13).</p><p><em><u>&nbsp;</u></em></p><p><em><u>Reduction in anti-FXa activity</u></em></p><p>The primary endpoint for both Study 14-503 (apixaban) and Study 14-504 (rivaroxaban) was the percent change in anti-FXa activity from baseline to post-infusion nadir.</p><p>&nbsp;</p><p>Among the apixaban-treated subjects in Study 14-503, the percent change in anti-FXa activity was</p><p>-92.34% (&plusmn; 2.809%) for the andexanet alfa group and -32.70% (&plusmn; 5.578%) for the placebo group (p &lt; 0.0001), the latter reflecting the intrinsic clearance of the anticoagulant.</p><p>&nbsp;</p><p>Among the rivaroxaban-treated subjects in Study 14-504, the percent change in anti-FXa activity</p><p>was -96.72% (&plusmn; 1.838%) for the andexanet alfa group and -44.75% (&plusmn; 11.749%) for the placebo group (p &lt; 0.0001), the latter reflecting the intrinsic clearance of the anticoagulant.</p><p>&nbsp;</p><p>The time courses of anti-FXa activity before and after andexanet alfa administration are shown in Figure 1. Reduction in anti-FXa activity correlates with restoration of thrombin generation. The anti- FXa activity thresholds for normalization of thrombin generation (defined by mean ETP and standard deviations) were estimated to be 44.2 ng/mL (within one standard deviation of normal ETP) based on pooled data from Studies 14-503 and 14-504, as indicated in the figure.</p><p><strong>Figure 1:&nbsp;&nbsp;&nbsp; Change in anti-FXa activity (ng/mL) in healthy subjects anticoagulated with apixaban (A) and rivaroxaban (B)</strong></p><p><img alt="" width="399" height="243" src="data:image/jpeg;base64,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" /></p><p>A</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><img alt="" width="403" height="226" src="data:image/png;base64,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" /></strong></p><p>B</p><p><em><u>Restoration of thrombin generation</u></em></p><p>In both, Study 14-503 and Study 14-504, treatment with andexanet alfa also resulted in a statistically significant increase in thrombin generation in healthy subjects anticoagulated with apixaban or rivaroxaban versus placebo (p &lt; 0.0001). Restoration of thrombin generation to within normal ranges (defined as one standard deviation from baseline levels) within two minutes and maintained for 20 hours was achieved with bolus only and bolus plus infusion for low-dose andexanet alfa in subjects on apixaban. For subjects on rivaroxaban, high-dose andexanet alfa (bolus plus infusion) resulted in increased thrombin generation above two standard deviations. No clinical evaluation for apixaban- treated subjects with high-dose andexanet alfa and no evaluation for rivaroxaban-treated subjects with low-dose andexanet alfa was performed in these studies.</p><p>&nbsp;</p><p><em><u>Change from baseline in free FXa inhibitor concentration at nadir</u></em></p><p>The mean unbound concentrations of apixaban and rivaroxaban were &lt; 3.5 ng/mL and 4 ng/mL, respectively, after bolus andexanet alfa administration and were maintained throughout the continuous infusion. These levels of unbound FXa inhibitor provide little or no anticoagulant effect.</p><p>&nbsp;</p><p><em><u>Reversal of FXa inhibitor anticoagulation in patients with acute major bleeding</u></em></p><p>In Study 14-505 (ANNEXA-4), a Phase IIIb/IV multinational, prospective, single-arm, open-label study, Andexxa was administered to 352 patients on FXa inhibitors who presented with acute major bleeding. The two co-primary endpoints are: a) percent change in anti-FXa activity from baseline to the nadir between five minutes after the end of the bolus until the end of the infusion, and; b) rate of good or excellent (compared to poor or none) haemostatic efficacy within 12 hours after infusion, as rated by an independent endpoint adjudication committee.</p><p>&nbsp;</p><p>In an updated interim analysis, data of 352 patients were evaluated.</p><p>&nbsp;</p><p>Approximately half of the patients were male, and the mean age was 77.4 years. Most patients had previously received either apixaban (194/352; 55.1%) or rivaroxaban (128/352; 36.4%), and experienced either an ICH (230/352; 65.3%) or a gastrointestinal (GI) bleed (94/352; 26.7%).</p><p>297/352 Patients (84.4%) received the low-dose regimen of andexanet, while 55 patients (15.6%) received the high-dose regimen.</p><p>&nbsp;</p><p>Of 352 enrolled patients, 249 (70.7%) were included in the efficacy-analysis. For these patients, median anti-FXa activity at baseline was 149.7 ng/mL for patients taking apixaban, and 211.8 ng/mL for patients taking rivaroxaban. Median change from baseline to nadir in anti-FXa activity was -93.4% (95% CI -94.3%, -92.4%) for apixaban, and -92.5% (95% CI -94.2%, -90.3%) for rivaroxaban.</p><p>&nbsp;</p><p>Haemostatic efficacy was good or excellent in 81.9% of 249 patients.</p><p>&nbsp;</p><p>The updated interim analysis demonstrated that the change in anti-FXa activity (surrogate) was not predictive for achievement of hemostatic efficacy in the overall patient population.</p><p>&nbsp;</p><p><u>Deaths</u></p><p>In the ANNEXA-4 study, of the patients in the safety population completing 30-day follow up (N=351), 54 patients (15.4%) died. The 30-day mortality rates were 16.2% (37/229) in patients presenting with ICH, 12.8% (12/94) with GI bleeding, and 17.9% (5/28) with other types of bleeding. The 30-day mortality rates were 20.1% (44/219) in patients aged &gt; 75 years old and 7.6% (10/132) in patients aged &le; 75 years. According to region, death rates were 22.1% (31/140) in patients recruited in the European Union and 10.9% (23/211) in patients recruited in North America. Compared with patients recruited in North America, EU patients were significantly older (79.0 years vs. 76.3 years), more frequently had ICH as index event (72.9% vs. 59.0%) and more ICHs were intraparenchymal (54.9% vs. 34.4%). Cardiovascular causes of death (n=27) included: haemorrhagic stroke (n=6), ischaemic stroke (n=5), sudden cardiac death (including unwitnessed) (n=5), cardiomechanical/pump failure (n=4), myocardial infarction (n=2), bleeding other than haemorrhagic stroke (n=1), and other cardiovascular causes (n=4). Non-cardiovascular deaths (n=27) included: respiratory failure (n=5), infection/sepsis (n=5), accident/trauma (n=2), cancer (n=1), and other/non-vascular cause (n=14).</p><p>&nbsp;</p><p><u>Thromboembolic events</u></p><p>In the ANNEXA-4 study, 36 (10.3%) patients experienced a total of 42 thromboembolic events: cerebrovascular accident (CVA) (15/42; 35.7%), deep venous thrombosis (13/42; 33.1%), acute myocardial infarction (8/42; 19.0%), pulmonary embolism (5/42; 11.9%), and transient ischaemic attack (1/42; 2.4%). The median time to event was nine days. A total of 33.3% of patients with thromboembolic events (12/36) experienced the thromboembolic event during the first three days. Of the 209 patients who were re-anticoagulated prior to a thrombotic event, 10 (4.8%) patients experienced a thromboembolic event. At the time of the event 10/36 (27.8%) patients were on antithrombotic therapy. The occurrence of thromboembolic events was generally comparable between patients &gt; 75 years (11.0%; 24/219) and those &le; 75 years of age (9.1%; 12/132).</p><p>&nbsp;</p><p>No thromboembolic events were observed in 223 healthy volunteers who received FXa inhibitors and were treated with andexanet alfa. Dose-dependent increases in coagulation markers F1+2, TAT, and D-dimers after administration of andexanet alfa were observed, but these markers were not measured in patients enrolled in the ANNEXA-4 study, and their relevance in bleeding patients is not known.</p><p>&nbsp;</p><p><em><u>Immunogenicity</u></em></p><p>345 andexanet alfa-treated healthy subjects were tested for antibodies cross reacting with andexanet alfa and antibodies to factor X and FXa. Treatment-emergent, non-neutralizing antibodies to andexanet alfa were detected in approximately 10% (35/345). These antibodies were generally low titre, and no clinical consequences were observed. No neutralising antibodies or antibodies to factor X or FXa were detected. To date, the occurrence of positive, non-neutralizing antibodies to andexanet alfa following treatment in patients in the ANNEXA-4 study (8.5% or 20/236 patients) has been similar to that observed in healthy subjects.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with andexanet alfa in one or more subsets of the paediatric population in treatment and prevention of FXa inhibitor-associated haemorrhages (see section 4.2 for information on paediatric use).</p><p>&nbsp;</p><p>Conditional approval</p><p>This medicinal product has been authorised under a so-called &lsquo;conditional approval&rsquo; scheme. This means that further evidence on this medicinal product is awaited. The European Medicines Agency will review new information on this medicinal product at least every year, and this SmPC will be updated as necessary.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Studies of andexanet alfa in the presence of direct FXa inhibitors in healthy subjects demonstrated dose proportional pharmacokinetics over the intended therapeutic dose range evaluated for both C<sub>max</sub>&nbsp;and area under the curve (AUC). FXa inhibitors did not affect andexanet alfa pharmacokinetics at therapeutic levels.</p><p><strong>Table 5. Pharmacokinetic parameters for Andexanet bolus-injection of 400 and 800mg</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>PK Parameter</p></td><td><p>400 mg Bolus</p></td><td><p>800 mg Bolus</p></td></tr><tr><td><p>AUC<sub>0-&infin;</sub> (hr*mg/mL)</p></td><td><p>61.3</p><p>[43.8, 94.9]</p></td><td><p>127</p><p>[57.5, 209]</p></td></tr><tr><td><p>Cmax (mg/mL)</p></td><td><p>61.0</p><p>[40.3, 98.5]</p></td><td><p>118</p><p>[50.2, 191]</p></td></tr><tr><td><p>Clearance (L/hr)</p></td><td><p>6.52</p><p>[4.21, 9.13]</p></td><td><p>6.29</p><p>[3.83, 13.9]</p></td></tr><tr><td><p>T<sub>1/2</sub> (hr)</p></td><td><p>3.78</p><p>[2.59, 6.39]</p></td><td><p>4.24</p><p>[2.47, 6.52]</p></td></tr><tr><td><p>Vss (L)</p></td><td><p>9.47</p><p>[6.08, 15.3]</p></td><td><p>8.94</p><p>[5.36, 23.1]</p></td></tr></tbody></table><p>Source : Study 19-514</p><p>Data presented are geometric mean [min, max]</p><p>&nbsp;</p><p><u>Pharmacokinetics in special populations</u></p><p><em>&nbsp;</em></p><p><em><u>Elderly population</u></em></p><p>In a study comparing andexanet alfa pharmacokinetics in elderly (65-69 years) and younger</p><p>(26-42 years) healthy subjects who had received apixaban, the pharmacokinetics of andexanet alfa in the elderly subjects were not statistically different than those in the younger subjects.</p><p><em>&nbsp;</em></p><p><em><u>Renal impairment</u></em></p><p>No trials have been conducted to investigate the pharmacokinetics of andexanet alfa in renally impaired patients. Based on the available PK data, andexanet alfa has little to no renal clearance, and thus would not require dose adjustment for patients with renal impairment.</p><p><em>&nbsp;</em></p><p><em><u>Hepatic impairment</u></em></p><p>No trials have been conducted to investigate the pharmacokinetics of andexanet alfa in patients with hepatic impairment. Biliary and/or faeces elimination of protein therapeutics is not a known route of protein elimination. Therefore, dose adjustment is not considered needed for patients with hepatic impairment.</p><p><em>&nbsp;</em></p><p><em><u>Gender</u></em></p><p>Based on population pharmacokinetics analysis, gender does not have a clinically meaningful effect on the pharmacokinetics of andexanet alfa.</p><p><em>&nbsp;</em></p><p><em><u>Paediatric population</u></em></p><p>The pharmacokinetics of andexanet alfa has not been studied in paediatric patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology and repeated dose toxicity studies up to two weeks in rats and monkeys.</p><p>&nbsp;</p><p>Studies to evaluate the mutagenic and carcinogenic potential of andexanet alfa have not been performed. Based on its mechanism of action and on the characteristics of proteins, no carcinogenic or genotoxic effects are anticipated.</p><p>&nbsp;</p><p>Animal reproductive and developmental studies have not been conducted with andexanet alfa.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tris hydrochloride 7.6 mg</p><p>L-arginine hydrochloride Sucrose 98 mg</p><p>Mannitol 518 mg</p><p>Polysorbate 80 (2.1 mg)</p><p>Tromethamine 6.7 mg &nbsp;</p><p>Sucrose 207 mg</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vial (unopened)
Three years stored at 2°C to 8°C.

Reconstituted medicinal product
Chemical and physical in-use stability has been demonstrated for 16 hours at 2°C to 8°C in the primary packaging vial. If needed, the reconstituted solution once transferred into the IV bag can be stored for an additional eight hours at room temperature. From a microbiological point of view, once reconstituted, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C to 8&deg;C).</p><p>Do not freeze.</p><p>For storage conditions after reconstitution of the medicinal product, see section 6.3.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Powder in a 20 mL vial (Type I glass) with a stopper (butyl rubber).</p><p>Pack size of four vials.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Reconstitution</u></p><p>The following are needed before starting reconstitution:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Calculated number of vials (see section 4.2).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Same number of 20 mL (or larger) solvent syringes equipped with a 20 gauge (or larger) needle.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alcohol swabs.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Large (50 mL or larger) sterile syringe. If a syringe pump is used for administration, multiple syringes should be used to contain the final volume of reconstituted product.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intravenous bags of polyolefin (PO) or polyvinyl chloride (PVC) material (150&nbsp;mL or larger) to contain the final volume of reconstituted product (if administration is performed with IV bags).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Water for injections.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.2 or 0.22 micron in-line polyethersulfone (PES) or equivalent low protein-binding filter.</p><p>&nbsp;</p><p>Andexanet alfa does not need to be brought to room temperature before reconstitution or administration to the patient. Aseptic technique during the reconstitution procedure should be used.</p><p>&nbsp;</p><p>Each vial is reconstituted according to the following instructions:</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp; Remove the flip-top from each vial.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp; Wipe the rubber stopper of each vial with an alcohol swab.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp; Using a 20 mL (or larger) syringe and a 20 gauge (or larger) needle, withdraw 20 mL of water for injections.</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp; Insert the syringe needle through the centre of the rubber stopper.</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp; Push the plunger down to slowly inject the 20 mL of water for injections into the vial, directing the stream toward the inside wall of the vial to minimise foaming.</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp; Gently swirl each vial, until all of the powder is completely dissolved. DO NOT SHAKE the vials, as this can lead to foaming. The dissolution time for each vial is approximately three to five minutes.</p><p>7.&nbsp;&nbsp;&nbsp;&nbsp; The reconstituted solution should be inspected for particulate matter and/or discolouration prior to administration. Do not use if opaque particles or discolouration are present.</p><p>8.&nbsp;&nbsp;&nbsp;&nbsp; For the most efficient reconstitution of the needed dose, and to minimise errors, inject each vial needed with 20 mL of water for injections before proceeding to the next step.</p><p>9.&nbsp;&nbsp;&nbsp;&nbsp; Use within eight hours after reconstitution when stored at room temperature.</p><p>&nbsp;</p><p><u>Administration using a syringe pump</u></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp; Once all required vials are reconstituted, the reconstituted solution is withdrawn from each vial, using the large volume (50 mL or larger) syringe equipped with a 20 gauge (or larger) needle.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp; The bolus and infusion are prepared in separate large volume syringes.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp; Due to the additional volume, the high dose bolus and infusion have to be further separated into additional syringes (two syringes apiece for bolus and infusion).</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp; To prevent the inadvertent transfer of air, be careful to hold the syringe needle up, and do not set the syringe down between multiple withdrawals from vials.</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp; Attach ancillary equipment (i.e., extension tubing, 0.2 or 0.22 micron in-line polyethersulfone (PES) or equivalent low protein-binding filter, syringe pump) in preparation for administration.</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp; Administer the reconstituted solution at the appropriate rate.</p><p>7.&nbsp;&nbsp;&nbsp;&nbsp; Discard all used syringes, needles, and vials, including any unused portion of reconstituted solution.</p><p>&nbsp;</p><p><u>Administration using intravenous bags</u></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp; Once all required vials are reconstituted, withdraw the reconstituted solution from each vial, using the large volume (50 mL or larger) syringe equipped with a 20 gauge (or larger) needle.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp; Transfer the reconstituted solution from the syringe into an appropriate IV bag.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp; Repeat steps 1 and 2 as necessary to transfer the complete volume of the bolus and the infusion into a PO or PVC IV bags.</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp; It is recommended that the bolus and infusion be split into two separate bags to ensure the correct administration rate. Although it is also permissible to use one PO or PVC IV bag for the bolus and infusion, the correct infusion rate must be ensured when switching from the bolus to the infusion.</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp; Attach ancillary equipment (i.e., extension tubing, 0.2 or 0.22 micron in-line polyethersulfone (PES) or equivalent low protein-binding filter, IV pump) in preparation for administration.</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp; Administer the reconstituted solution at the appropriate rate.</p><p>&nbsp;</p><p><u>Disposal</u></p><p>All used syringes, needles, and vials, including any unused portion of reconstituted solution, should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AstraZeneca AB
SE-151 85 Södertälje
Sweden

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                March 2025
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>